搜尋結果
3 天前 · BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T...
- Biontech Se
- An Exit Ramp Or On-Ramp For Investors?
- What's Next For Biontech
- Surviving in The Meantime
The problem investors see is that collaboration revenue is already slumpingas the COVID-19 pandemic ebbs. In the second quarter, the company reported $3.4 billion in revenue, down 111% from the same period a year ago, and earnings per share of $6.87, down from $14.56 a year earlier. That kind of decline explains why the vaccine stock is trading for...
Let's start with the positives. BioNTech, as of the last quarter, had 9.3 billion euros in cash (roughly $9.2 billion). That will go a long way toward helping the company develop its promising pipeline, which has 20 ongoing clinical trials, including five therapies in phase 2 trials and one in a phase 3 trial. The lone phase 3 trial is for BNT161, ...
It will likely take several years for any of the company's oncology vaccines to pay off; in the meantime, earnings will likely decline and the stock's price could continue to suffer. However, at some point, the company should become a less risky long-term bet with plenty of upside. It has plenty of cash. And all it would take is for one or two of i...
2023年10月25日 · BioNTech (BNTX-0.44%) is the lesser-known member of the pair -- which also includes Pfizer -- that developed and marketed Comirnaty, one of the leading coronavirus vaccines on the market.
2022年1月24日 · Pipeline scaleup points to an even bigger future. Over the next three years, expect BioNTech to pour funds and energy into its development pipeline. Last year, the company expanded its research...
2022年3月2日 · Although shares of biotech company BioNTech (BNTX 0.52%) have recently fallen along with most other stocks, the vaccine maker's performance over the past 12 months remains above that of the ...
2021年8月1日 · The technology had never been approved for a vaccine in humans. Yet, dig a little deeper and Moderna ( MRNA 7.57%) and BioNTech ( BNTX 1.52%) differ in important ways. They began differently, they ...
2023年6月2日 · BioNTech's shares have fallen this year, along with its revenue. The company said it expects $5 billion in 2023 revenue from its COVID-19 vaccine, Comirnaty. BioNTech plans to start a phase 3 ...
